PHVS logo

PHVS
Pharvaris NV

912
Mkt Cap
$1.83B
Volume
244,410.00
52W High
$29.85
52W Low
$11.51
PE Ratio
-8.88
PHVS Fundamentals
Price
$28.56
Prev Close
$29.45
Open
$28.12
50D MA
$27.07
Beta
0.76
Avg. Volume
176,423.03
P/B
5.06
Loading...
Loading...
Poll

Earnings Recap

Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.

Bullish

Pharvaris's deucrictibant demonstrated strong efficacy and safety in pivotal HAE trials, with plans for NDA submission in 2026. The company is expanding indications and leveraging its intellectual property and experienced team for future growth.

Bearish

Pharvaris faces significant financial challenges with ongoing losses and dependence on future funding. Clinical trial setbacks and intense competition, coupled with regulatory and pricing uncertainties, pose substantial risks to commercial success.

Latest PHVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.